This article is more than 5 years old. Information may no longer be current.
Prognostic risk factors identified for HPV-associated OSCC
Click Here to Manage Email Alerts
Older age, advanced clinical T classification and tobacco use were associated with shorter survival among patients with HPV-associated oropharyngeal squamous cell carcinoma, according to study results.
Advanced clinical T classification, prior or current alcohol use and unmarried status were associated with disease recurrence, researchers wrote.
The researchers conducted the investigation to evaluate predictors of survival in a cohort of 176 individuals with incident HPV-associated oropharyngeal squamous cell carcinoma who had been treated at Johns Hopkins Hospital between 1997 and 2008.
Patients in the cohort had tissue available for HPV testing by in situ hybridization and/or immunohistochemistry, as well as demographic and clinicopathologic data available for analysis.
Ninety percent (n=157) of patients in the cohort had HPV-associated disease. Among that subset of patients, the 3-year OS was 93% (95% CI, 88%-98%) and the 5-year OS was 89% (95% CI, 81%-97%).
Older patients demonstrated shorter survival (HR=2.33 per 10-year increase; 95% CI, 1.05-5.16), as did those with advanced clinical T classification (HR=5.78; 95% CI, 1.60-20.8) and current tobacco users (HR=4.38; 95% CI, 1.07-18.0).
Patients with advanced clinical T-classification were more likely to experience recurrence (HR=8.32; 95% CI, 3.06-23), as were current/former alcohol users (HR=13; 95% CI, 1.33-120) and those who were unmarried (HR=3.28; 95% CI, 1.20-9.0).
Patients who did not recur within 5 years carried an 8.6% chance of recurrence by the 10-year point post-definitive therapy (one-sided 95% CI upper bound, 19%; P=.088).
“It is noteworthy that we observed a trend toward increased risk of recurrence after the conventional 5-year cancer surveillance period subsequent to definitive therapy,” the researchers wrote. “This trend needs to be investigated further to determine whether extended cancer surveillance is warranted in this ... population.”
Disclosure: The researchers report no relevant financial disclosures.
Click Here to Manage Email Alerts